Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients

International Journal of Cancer

Volumn 111, Issue 2, 2004, Pages 252-258

  Paradiso, Angelo ^a   Xu, Janming ^a   Mangia, Anita ^a   Chiriatti, Annalisa ^a   Simone, Gianni ^a   Zito, Alfredo ^a   Montemurro, Severino ^a   Giuliani, Francesco ^a   Maiello, Evaristo ^a   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; CPT 11; Predictive factor; Topoisomerase I

Indexed keywords

DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 3142660249     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20208     Document Type: Article

References (34)

1. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer: a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-81.
2. Cummingham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
3. Rustum YM, Cao S. New drugs in therapy of colorectal cancer: preclinical studies. Semin Oncol 1999;26:612-20.
4. Guichard S, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998;55:667-76.
5. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
6. Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2001;84:1-7.
7. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997;89:308-13.
8. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997;15:1923-31.
9. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1992;10:3223-9.
10. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG. Thymidylate synthase and P53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000;82:560-7.
11. Paradiso A, Rabinovich M, Vallejo C, Machiavelli M, Romero A, Perez J, Lacava J, Cuevas MA, Rodriquez R, Leone B, Sapia MG, Simone G, et al. P53 and PCNA expression in advanced colorectal cancer, response to chemotherapy and long-term prognosis. Int J Cancer 1996;69:437-41.
12. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000;6:1378-84.
13. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995;55:2116-21.
14. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997;70:335-40.
15. Saltz L, Danenberg K, Paty P, Kelsen D, Salonga D, Park JM, Danenberg P. High thymidylate synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998;17:991 (abstract).
16. Kigawa J, Takahashi M, Minagawa Y, Oishi T, Sugiyama T, Yakushiji M, Terakawa N. Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer. Int J Cancer 1999;84:521-4.
17. Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Cigolari S, Fortunato S, Pedicini T, Borsellino N, Lopez M, Colucci G. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomized phase II study of the Southern Italy Oncology Group. Ann Oncol 2000;11:1045-51.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
19. Holden JA, Rhn MP, Jolles CJ, Vorobyev SV, Bronstein IB. Immunohistochemical detection of DNA topoisomerase I in formalin-fixed, paraffin wax-embedded normal tissues and in ovarian carcinomas. Mol Pathol 1997;50:247-53.
20. Johnston PG, Liang CM, Henry S, Chabner BA, Allegra CJ. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 1991;51:6668-76.
21. Paradiso A, Simone G, De Lena M, Leone B, Vallejo C, Lacava J, Dellapasqua S, Daidone MG, Costa A. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 2001;84:651-8.
22. Ichikawa W, Uetake H, Nihei Z, Mastuo K, Fujita H, Yamada Y. Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC). Proc Am Soc Clin Oncol 1999;18:946 (abstract).
23. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-46.
24. Harisi R, Dudas J, Winternitz T, Jaray B, Kovalsky I, Bodoly G. Prediction of irinotecan efficiency in colorectal cancer. Proc Am Soc Clin Oncol 2001;20:2243 (abstract).
25. Thirion P, Wolmark N, Haddad E, Buyse M, Piedbois P. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses-Meta-Analysis Group in Cancer. Ann Oncol 1999;10:1317-20.
26. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared to the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000;6:4797-802.
27. Johnston PG, Benson III AB, Catalano P, Rao SM, Dwyer PJ, Allegra CJ. Thymidylate Synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to Fluorouracil in metastatic disease sites. J Clin Oncol 2003;21:815-9.
28. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, Navabi H, Miller KD, Balaton AJ. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002;117:81-9.
29. Tomiak A, Vincent M, Earle CC, Johnston PG, Kocha W, Taylor M, Maroun J, Eidus L, Whiston F, Stitt L. Thymidilate Synthase expression in stage II and III colon cancer. Am J Clin Oncol 2001;24:597-602.
30. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5Fu failure. CPT-11 F205, F221 and V222 study group. Br J Cancer 2000;83:431-7.
31. Xu Y, Villalona-Calero. Irinotecan: mechanisms of tumour resistance and novel strategies for modulating its activity. Ann Oncol 2002;13:1841-51.
32. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, Selves J, Chatelut E, Bugat R, Canal P. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br J Cancer 1999;80:364-70.
33. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of Irinotecan. Clin Cancer Res 2002;8:2605-11.
34. Jonker DJ, Maroun JA, Le Francois B, Dahrouge S, Birnboim HC. Correlation between 2 thymidylate synthase gene polymorphisms and clinical outcomes in colorectal cancer patients receiving adjuvant chemotherapy. Proc Am Soc Clin Oncol 2002;21:638 (abstract).